About Apheris
At Apheris, we are building the future of how AI is applied in pharmaceutical R&D.
Our federated computing technology enables global pharma companies to collaborate securely on large AI models that accelerate drug discovery, without ever sharing their proprietary data. By powering multi-partner data networks across small molecules, antibodies, and protein folding, Apheris is redefining how science and AI intersect.
We currently host two flagship networks: the AI Structural Biology (AISB) Network, focused on protein co-folding and binding affinity prediction, and the ADMET Network, focused on small-molecule property prediction. In addition, we have just launched ApherisFold, an enterprise co-folding application that enables pharma teams to deploy cutting-edge models such as OpenFold 3 and Boltz-2 directly within their own environments.
Our federated computing technology enables global pharma companies to collaborate securely on large AI models that accelerate drug discovery, without ever sharing their proprietary data. By powering multi-partner data networks across small molecules, antibodies, and protein folding, Apheris is redefining how science and AI intersect.
We currently host two flagship networks: the AI Structural Biology (AISB) Network, focused on protein co-folding and binding affinity prediction, and the ADMET Network, focused on small-molecule property prediction. In addition, we have just launched ApherisFold, an enterprise co-folding application that enables pharma teams to deploy cutting-edge models such as OpenFold 3 and Boltz-2 directly within their own environments.